A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Principal Investigator
Thalia FieldOverview
Body Locations and Systems
StrokeDiagnosis and Therapy
Stroke RehabilitationClinicalTrials.gov#
NCT02930018Status
Closed for RecruitmentStudy Start/End
Jul 25, 2017 to Dec 31, 2020Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Genoveva Maclean / Study CoordinatorPhone
604-875-4111 Ext: 62100Email Address
genoveva@bcstrokecentre.caPurpose of Study
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.
Eligibility
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.